Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Pastina, Ilaria ^a,b   Giovannetti, Elisa ^c,d   Chioni, Aldo ^a,b   Sissung, Tristan M ^e   Crea, Francesco ^c   Orlandini, Cinzia ^a   Price, Douglas K ^e   Cianci, Claudia ^a   Figg, William D ^e   Ricci, Sergio ^a   Danesi, Romano ^c  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b Grosseto Hospital   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ARGININE; ASPARAGINE; CYTIDINE; CYTOCHROME P450 1B1; DOCETAXEL; GLYCINE; GUANOSINE; LEUCINE; PREDNISONE; SERINE; VALINE; ANTINEOPLASTIC AGENT; CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; TAXOID; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; DRUG FATALITY; DRUG RESPONSE; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY RESISTANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 77957152348     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-511     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C, . Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002, 60(3 Suppl 1):1-6. 10.1016/S0090-4295(02)01559-5, 12231036, Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer.
3. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in treatment of prostatic carcinoma. J Clin Oncol 1985, 3:827-841.
4. Tannock IF, De Wit R, Berry WR, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus Prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. 10.1056/NEJMoa040720, 15470213.
5. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and Estramustine compared with Mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520. 10.1056/NEJMoa041318, 15470214.
6. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodinamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998, 16:187-196.
7. Bournique B, Lemarie A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos 2002, 30:1149-1152. 10.1124/dmd.30.11.1149, 12386117.
8. Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006, 4:135-150. 10.1158/1541-7786.MCR-05-0101, 16547151.
9. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001, 62:207-212. 10.1016/S0006-2952(01)00643-8, 11389879.
10. Martinez VG, O'Connor R, Liang Y, Clynes M. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer 2008, 98:564-570. 10.1038/sj.bjc.6604195, 2243158, 18212750.
11. Sissung TM, Danesi R, Price KM, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008, 1:19-26.
12. Landi MT, Bergen AW, Baccarelli A, Patterson DG, Grassman J, Ter-Minassian M, Mocarelli P, Caporaso N, Masten SA, Pesatori AC, Pittman GS, Bell DA. CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology 2005, 207:191-202. 10.1016/j.tox.2004.08.021, 15596250.
13. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999, 20:1607-1613. 10.1093/carcin/20.8.1607, 10426814.
14. McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, Ingelman-Sundberg M. Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys 2000, 378:175-181. 10.1006/abbi.2000.1808, 10871058.
15. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005, 67:435-443. 10.1124/mol.104.006056, 15486049.
16. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010, 9:581-593. 10.1158/1535-7163.MCT-09-0665, 20159991.
17. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000, 10:761-766. 10.1097/00008571-200012000-00001, 11221602.
18. The SNP500Cancer Database. , http://snp500cancer.nci.nih.gov
19. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003, 29:407-415. 10.1016/S0305-7372(03)00097-5, 12972359.
20. Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 2001, 28(4 Suppl 14):37-44. 10.1016/S0093-7754(01)90058-2, 11605182.
21. Hitzl M, Drescher S, Van Der Kuip H, Schäffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001, 11:293-298. 10.1097/00008571-200106000-00003, 11434506.
22. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2009, 78:49-55. 10.1159/000158454, 18812689.
23. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007, 25:4528-4535. 10.1200/JCO.2006.10.4752, 17925548.
24. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008, 14:4543-4549. 10.1158/1078-0432.CCR-07-4230, 2723795, 18628469.
25. Chaib H, Cockrell EK, Rubin MA, Macoska JA. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 2001, 3:43-52. 10.1038/sj.neo.7900126, 1505021, 11326315.
26. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003, 64:659-669. 10.1124/mol.64.3.659, 12920202.
27. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010, 46:517-525. 10.1016/j.ejca.2009.11.007, 20005697.
28. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008, 101(Suppl 2):11-15. 10.1111/j.1464-410X.2007.07485.x, 18307687.
29. Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology 2004, 63:321-326. 10.1016/j.urology.2003.09.044, 14972482.
30. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?. J Pharmacol Exp Ther 2001, 296:537-541.
31. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994, 91:3964-3968. 10.1073/pnas.91.9.3964, 43703, 8171020.
32. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000, 10:343-353. 10.1097/00008571-200006000-00008, 10862525.
33. Brandi G, de Rosa F, Danesi R, Montini GC, Biasco G. Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?. Eur Urol 2008, 54:938-941. 10.1016/j.eururo.2008.07.029, 18657896.
34. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007, 7:362-365. 10.1038/sj.tpj.6500434, 17224914.